Q-omics provides the consensus-scored TUBA1A profile across patient tissues and cancer cell-line models. TUBA1A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TUBA1A is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, TUBA1A RNA expression shows 17,535 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRP, and TGCT as cancer lineages where TUBA1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA1A survival associations across molecular data types. TUBA1A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA1A RNA expression–survival associations across cancer types. High TUBA1A expression shows unfavorable associations in MESO, BLCA, LGG, UVM and STAD, but favorable associations in PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TUBA1A RNA expression.
This table summarizes TUBA1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBA1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA1A shows lower tumor expression in BLCA, LUAD and KICH and higher tumor expression in KIRP, KIRC and LIHC. The KIRP box plot shows higher TUBA1A RNA expression in tumor versus normal tissue (log2 FC = +1.767, t-test p < 0.001).
This table shows molecular features associated with TUBA1A in patient tissues and cancer cell lines. In patient samples, TUBA1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
